Coronavirus Vaccine / Columbia University - LARVOL DELTA

Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials. (PubMed, JAMA Netw Open) - "This secondary cross-protocol analysis constructed TND study datasets from study sites in 16 countries across 5 continents using the blinded phase cohorts of 5 harmonized phase 3 COVID-19 Prevention Network RCTs: COVE (Coronavirus Vaccine Efficacy and Safety), AZD1222, ENSEMBLE, PREVENT-19 (Prefusion Protein Subunit Vaccine Efficacy Novavax Trial COVID-19), and VAT00008...Participants received vaccines consisting of messenger RNA-1273 (COVE; 2 doses 28 days apart), ChAdOx1 nCoV-19 (AZD1222; 2 doses 28 days apart), Ad26.COV2.S (ENSEMBLE; 1 dose), NVX-CoV2373 (PREVENT-19; 2 doses 21 days apart), CoV2 preS dTM-AS03 (VAT00008; D614) (2 doses 21 days apart), or CoV2 preS dTM-AS03 (D614 plus B.1.351) (VAT00008; 2 doses 21 days apart) or placebo...In this cross-protocol analysis, the TND provided reliable inferences on COVID-19 vaccine effectiveness in health care-seeking populations for multiple vaccines and symptom definitions when confounding and selection bias were absent...."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

[VIRTUAL] 112 - Novel Vaccination strategies against Respiratory Infections (IDWeek 2021) - "Learning Objectives: At the conclusion of this session, participants will be able to:describe the potential approaches and likelihood of success of developing a pan influenza vaccine describe the potential approaches and likelihood of success of developing a pan coronavirus vaccine describe the major mechanisms of immune protection in the lung and their stimulation by vaccination"

Infectious Disease • Novel Coronavirus Disease

IMPROVE: Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 (clinicaltrials.gov) - P4; N=100; Not yet recruiting; Sponsor: Columbia University

Clinical • New P4 trial • Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Thrombosis • Venous Thromboembolism

Coronavirus Disease 2019 (COVID-19) Seroprevalence and Mental Health Burden Among Healthcare Workers (clinicaltrials.gov) - P=N/A; N=1000; Recruiting; Sponsor: Columbia University

New trial • CNS Disorders • Infectious Disease • Novel Coronavirus Disease • Psychiatry

Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) (clinicaltrials.gov) - P2/3; N=1600; Recruiting; Sponsor: Columbia University; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

Saved From COVID-19 (clinicaltrials.gov) - P2; N=350; Recruiting; Sponsor: Columbia University

New P2 trial

Acquiring Convalescent Specimens for COVID-19 Antibodies (clinicaltrials.gov) - P=N/A; N=12; Recruiting; Sponsor: Columbia University; Not yet recruiting ➔ Recruiting

Enrollment open • CD27

Acquiring Convalescent Specimens for COVID-19 Antibodies (clinicaltrials.gov) - P; N=12; Not yet recruiting; Sponsor: Columbia University

New trial

Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) (clinicaltrials.gov) - P2/3; N=1600; Not yet recruiting; Sponsor: Columbia University

Clinical • New P2/3 trial

Coronavirus treatment: Vaccines/drugs in the pipeline for Covid-19 (Clinical Trials Arena) - "Researchers at Columbia University have been awarded a $2.1m grant by the Jack Ma Foundation to develop a coronavirus cure. Four different teams at the university will adopt various approaches towards the development of a vaccine against coronavirus."

Grant